Literature DB >> 29166526

Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis.

Lívia Arroyo Trídico1, João Roberto Antonio1,2, Carlos Eduardo Mathias1, Eurides Maria de Oliveira Pozetti1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29166526      PMCID: PMC5674720          DOI: 10.1590/abd1806-4841.20176565

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


× No keyword cloud information.
  6 in total

Review 1.  Psoriasis--epidemiology and clinical spectrum.

Authors:  E Christophers
Journal:  Clin Exp Dermatol       Date:  2001-06       Impact factor: 3.470

2.  Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation.

Authors:  Misha Rosenbach; Sylvia Hsu; Neil J Korman; Mark G Lebwohl; Melodie Young; Bruce F Bebo; Abby S Van Voorhees
Journal:  J Am Acad Dermatol       Date:  2009-08-08       Impact factor: 11.527

Review 3.  [Infliximab].

Authors:  E Herrera; S Habicheyn
Journal:  Actas Dermosifiliogr       Date:  2008-07

Review 4.  Long-term efficacy of biologics in dermatology.

Authors:  Leslie Castelo-Soccio; Abby S Van Voorhees
Journal:  Dermatol Ther       Date:  2009 Jan-Feb       Impact factor: 2.851

5.  Erythrodermic Psoriasis Treated with Golimumab: A Case Report.

Authors:  Won-Ku Lee; Gun-Wook Kim; Hyun-Ho Cho; Won-Jeong Kim; Je-Ho Mun; Margaret Song; Hoon-Soo Kim; Hyun-Chang Ko; Moon-Bum Kim; Byung-Soo Kim
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

Review 6.  Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.

Authors:  Philip J Mease; April W Armstrong
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

  6 in total
  1 in total

Review 1.  Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

Authors:  Shuai Shao; Gang Wang; Emanual Maverakis; Johann E Gudjonsson
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.